The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study by Khalid Al Sulaiman, Khalid Al Sulaiman, Khalid Al Sulaiman, Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Shmeylan Al Harbi, Shmeylan Al Harbi, Shmeylan Al Harbi, Abdulrahman Al Shaya, Abdulrahman Al Shaya, Abdulrahman Al Shaya, Hisham A. Badreldin, Hisham A. Badreldin, Hisham A. Badreldin, Raed Kensara, Raed Kensara, Abdullah F. Alharthi, Abdullah F. Alharthi, Jahad Alghamdi, Ahad Alawad, Rand Alotaibi, Abdullah Kharbosh, Hessa Al Muqati, Abdulmohsen Alhuwahmel, Mohammed Almusallam, Ghada Albarrak, Ibrahim Al Sulaihim, Bader Alanazi, Bodoor S. Al-Dosari, Ramesh Vishwakarma, Alawi S. Alsaeedi, Alawi S. Alsaeedi, Alawi S. Alsaeedi, Ghassan Al Ghamdi, Ghassan Al Ghamdi, Ghassan Al Ghamdi, Hadeel Alkofide, Hasan M. Al-Dorzi, Hasan M. Al-Dorzi, Hasan M. Al-Dorzi

Connect to this object online.